Last 45 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -55.31 | — | — | — | — | — | 2.36 | — | — | — | — | — | 1.62 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 4.82 | 2.26 | 2.62 | 1.45 | 2.32 | 3.03 | 4.20 | 4.29 | 5.28 | 6.36 | 5.29 | 1.97 | 0.74 |
| — | -25.5% | -37.5% | -66.2% | -56.1% | -52.4% | -20.6% | +117.7% | +609.2% | +73.2% | -75.2% | -21.6% | -94.1% | |
| P/B Ratio | 3.64 | 2.34 | 2.95 | 1.69 | 1.95 | 2.77 | 2.90 | 5.23 | 5.10 | 5.37 | 3.46 | 4.00 | 2.83 |
| — | -15.6% | +1.4% | -67.6% | -61.7% | -48.3% | -16.0% | +30.8% | +80.5% | -52.2% | -72.4% | -75.6% | -82.1% | |
| P/FCF | — | — | — | 13.55 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 26.27 | — | — | — | — | — | 2.22 | — | — | — | — | — | 0.94 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 64.88 | — | — | — | — | — | 2.22 | — | — | — | — | — | 1.18 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Valneva SE's operating margin was -22.5% in Q2 2025, down 10.4 pp QoQ and up 34.1 pp YoY. The trailing four-quarter average of -25.3% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 30.7% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 41.9% | 50.1% | 53.2% | 48.6% | 44.0% | 38.3% | 32.3% | 37.8% | 44.9% | 17.1% | 38.9% | -9.3% | 80.1% |
| — | +30.7% | +64.5% | +28.5% | -2.1% | +124.3% | -16.8% | +508.2% | -43.9% | +114.1% | +6.3% | -110.3% | +367.6% | |
| Operating Margin | 7.9% | -22.5% | -12.1% | -39.4% | -27.2% | -56.6% | 208.2% | -59.4% | -58.3% | -45.7% | -49.5% | -50.6% | 59.6% |
| — | +60.3% | -105.8% | +33.6% | +53.4% | -23.8% | +521.0% | -17.5% | -198.0% | +75.3% | +41.3% | -179.9% | +126.3% | |
| Net Margin | -7.2% | -24.0% | -18.8% | -69.9% | -20.2% | -65.5% | 179.9% | -76.8% | -89.9% | -42.1% | -54.1% | -39.7% | 46.2% |
| — | +63.4% | -110.4% | +9.0% | +77.6% | -55.8% | +432.5% | -93.4% | -294.5% | +79.4% | +54.6% | -164.0% | +119.1% |
| Metric | TTM | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -7.9% | -6.4% | -5.2% | -18.6% | -4.8% | -14.0% | 36.1% | -21.8% | -19.7% | -8.6% | -8.5% | -23.0% | 56.1% |
| — | +54.3% | -114.4% | +14.9% | +75.5% | -63.9% | +522.2% | +5.1% | -135.0% | +92.9% | +47.7% | -116.5% | +161.8% | |
| ROA | -2.6% | -2.4% | -1.9% | -7.3% | -1.9% | -5.1% | 12.1% | -6.5% | -6.4% | -3.0% | -3.0% | -6.7% | 10.2% |
| — | +52.8% | -115.5% | -12.0% | +70.8% | -72.2% | +504.9% | +3.0% | -163.3% | +84.6% | +8.3% | -130.3% | +214.4% | |
| ROIC | 4.5% | -3.6% | -1.9% | -6.4% | -3.7% | -6.9% | 23.0% | -9.3% | -10.5% | -11.6% | -13.4% | -57.0% | 106.8% |
| — | +48.1% | -108.4% | +31.6% | +65.0% | +40.4% | +272.0% | +83.7% | -109.9% | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 13.7% YoY to 2.27x, tightening the short-term liquidity position.
| Metric | TTM | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.19 | 1.06 | 1.20 | 1.19 | 0.93 | 1.26 | 1.12 | 1.52 | 1.23 | 0.78 | 0.75 | 0.69 | 0.98 |
| — | -16.2% | +7.7% | -21.4% | -25.1% | +61.1% | +50.0% | +118.9% | +26.0% | -45.3% | -4.2% | +3.1% | -32.3% | |
| Debt / EBITDA | 6.57 | — | — | — | — | — | 3.21 | — | — | — | — | — | 1.65 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.61 | 2.27 | 2.70 | 2.61 | 2.78 | 2.63 | 2.64 | 1.65 | 1.47 | 1.42 | 1.48 | 1.53 | 1.27 |
| — | -13.7% | +2.5% | +57.7% | +89.2% | +85.4% | +78.4% | +8.1% | +15.4% | +22.6% | -1.4% | -3.6% | +3.5% | |
| Quick Ratio | 2.14 | 1.77 | 2.12 | 2.14 | 2.25 | 2.15 | 2.22 | 1.37 | 1.30 | 1.28 | 1.33 | 1.40 | 1.02 |
| — | -17.4% | -4.4% | +55.8% | +73.8% | +68.1% | +66.8% | -2.1% | +27.6% | +36.5% | +19.3% | +12.2% | +6.4% | |
| Interest Coverage | 0.56 | -1.94 | -1.00 | -3.33 | -2.17 | -4.36 | 9.68 | -2.30 | -6.17 | -4.86 | -3.25 | -9.96 | 17.96 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 45 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonValneva SE's current P/E is -55.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Valneva SE's current operating margin is 7.9%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Valneva SE's business trajectory between earnings reports.